CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18,955 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01511458
NCT01511458N/ACompleted

Non-invasive Chromosomal Examination of Trisomy

Roche Sequencing Solutions·observational·Posted Jan 18, 2012·Updated Jul 14, 2014

In Brief

An observational study for Trisomy 21. Completed, enrolled 18,955 participants across 36 sites in 6 countries.

Detailed Summary

The purpose of this blinded, multi-center, prospective, case-controlled study is to compare the Ariosa Harmony™ Prenatal Test for trisomy 21 detection with a standard first-trimester prenatal screening test consisting of serum screening (PAPP-A,free beta-hCG \[β-hCG\] or total hCG) and a nuchal translucency (NT) measurement (i.e. combined first trimester screening) in a general screened population. The performance characteristics of these two test modalities will be assessed relative to the clinical reference standard of genetic analysis of the fetus or phenotypic characterization and genetic analysis of the newborn.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTrisomy 21
CountriesBelgium, Canada, Italy, Netherlands, Sweden, United States

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 18, 2012
Enrollment StartMar 1, 2012
Primary CompletionNov 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.5 years ago